Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease
Pharmaceutical Technology
APRIL 3, 2023
Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) against an undisclosed target, primarily focusing on coeliac disease. In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.
Let's personalize your content